Vestal Point Capital LP Buys Shares of 1,250,000 Roivant Sciences Ltd. (NASDAQ:ROIV)
Vestal Point Capital LP bought a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,250,000 shares of the company's stock, valued at approximately $14,788,000. Vestal Point Capital LP owned about 0.17% of Roivant Sciences at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Barclays PLC lifted its position in Roivant Sciences by 19.7% during the third quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after purchasing an additional 75,609 shares during the last quarter. Elevate Capital Advisors LLC bought a new stake in Roivant Sciences during the fourth quarter valued at approximately $2,116,000. Thompson Siegel & Walmsley LLC lifted its position in Roivant Sciences by 10.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock valued at $6,688,000 after purchasing an additional 51,705 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Roivant Sciences during the fourth quarter valued at approximately $995,000. 64.76% of the stock is currently owned by institutional investors.
In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the transaction, the insider now directly owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at approximately $9,551,654.85. The trade was a 10.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,223,959 shares of company stock valued at $13,420,035. 7.90% of the stock is currently owned by corporate insiders.
Several equities research analysts have issued reports on ROIV shares. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Monday, April 21st.
Get Our Latest Analysis on ROIV
ROIV stock opened at $10.79 on Monday. The company has a market capitalization of $7.70 billion, a PE ratio of -71.93 and a beta of 1.23. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The company's 50 day moving average price is $10.51 and its two-hundred day moving average price is $11.07.
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
